Linker C A, Levitt L J, O'Donnell M, Ries C A, Link M P, Forman S J, Farbstein M J
Blood. 1987 Apr;69(4):1242-8.
We designed a treatment program to improve the outcome for adults with acute lymphoblastic leukemia (ALL). Treatment included a remission-induction phase followed by intensive alternating cycles of non-cross-resistant chemotherapy and prolonged oral maintenance therapy. Eighty-one consecutive previously untreated patients were entered on this study. Ninety-four percent of patients entered complete remission. A Kaplan-Meier analysis predicts that 53% +/- 9% (SEM) of patients in remission will remain free of disease at 3 years. Neither age, sex, WBC count, nor immunophenotype had a significant effect on remission duration. This program of intensive cyclical chemotherapy has improved the disease-free survival of patients with adult ALL.
我们设计了一个治疗方案来改善成年急性淋巴细胞白血病(ALL)患者的治疗结果。治疗包括一个诱导缓解阶段,随后是密集的非交叉耐药化疗交替周期以及延长的口服维持治疗。81例连续的既往未接受过治疗的患者进入了本研究。94%的患者进入完全缓解。一项Kaplan-Meier分析预测,缓解期患者中有53%±9%(标准误)在3年时将无疾病生存。年龄、性别、白细胞计数和免疫表型均对缓解持续时间无显著影响。这种密集的周期性化疗方案改善了成年ALL患者的无病生存率。